Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Net Income (Common)
Ondine Biomedical Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Net Income (Common)
-CA$14.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Net Income (Common)
-$5m
|
CAGR 3-Years
49%
|
CAGR 5-Years
39%
|
CAGR 10-Years
10%
|
|
|
Profound Medical Corp
TSX:PRN
|
Net Income (Common)
-$27.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Opsens Inc
TSX:OPS
|
Net Income (Common)
-CA$12.4m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-18%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Net Income (Common)
-CA$4.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
|
MedMira Inc
XTSX:MIR
|
Net Income (Common)
-CA$3.8m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Net Income (Common)?
Net Income (Common)
-14.4m
CAD
Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Net Income (Common) amounts to -14.4m CAD.
What is Ondine Biomedical Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
26%
Over the last year, the Net Income (Common) growth was 26%.
You don't have any saved screeners yet